<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872309</url>
  </required_header>
  <id_info>
    <org_study_id>STH20825</org_study_id>
    <nct_id>NCT04872309</nct_id>
  </id_info>
  <brief_title>MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology</brief_title>
  <acronym>MURDOCH</acronym>
  <official_title>MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheffield Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung magnetic resonance imaging (MRI) with proton and inhaled inert gases has demonstrated a&#xD;
      clinical ability to provide valuable structural and functional information in lung disease.&#xD;
      Advances in lung MRI methods have led to our department handling clinical imaging referrals&#xD;
      from local and national respiratory units. Hyperpolarised Xenon-129 gas MRI is now the&#xD;
      gold-standard MRI modality used in clinical practice for asthma and COPD in Sheffield.&#xD;
&#xD;
      In this new study we will use Xenon gas MR imaging and 19F gas MR imaging to obtain&#xD;
      physiological, structural, and functional information about patients with known respiratory&#xD;
      disease, namely asthma and COPD. Up to 20 patients with asthma and up to 20 patients with&#xD;
      COPD will be recruited. Study visits will involve lung function tests and imaging using&#xD;
      proton MRI, hyperpolarised xenon gas MRI, and 19F perfluoropropane MRI. After initial&#xD;
      baseline assessments, patients will be followed up after 3 and 6 years to investigate the&#xD;
      utility of MRI and lung function measurements in tracking disease progression over time.&#xD;
&#xD;
      In addition, during the COVID-19 pandemic will also be studying the long term effects of this&#xD;
      novel disease. We will use Xenon gas MR imaging and pulmonary vascular 1H MR imaging to&#xD;
      obtain physiological, structural, and functional information about patients with COVID-19,&#xD;
      including hospitalised patients and mild, non-hospitalised COVID-19 patients. Participants&#xD;
      may be invited for baseline assessments during the symptomatic phase of the disease and/or be&#xD;
      followed up after 6, 12, 24 and 52 weeks (in line with clinical follow up for hospitalised&#xD;
      patients) to investigate long term effects of this novel disease.&#xD;
&#xD;
      Our novel approach will provide mechanistic insight in to clinical observations such as : (i)&#xD;
      why previously healthy patients can respond so poorly to oxygen/ventilation therapy, (ii) why&#xD;
      patients respond to proning, and (iii) whether this is caused by alveolar-capillary&#xD;
      interstitial changes and /or microvascular clotting in the pulmonary vasculature (leading to&#xD;
      V/Q mismatch), and (iv) whether these acute changes lead to long term interstitial lung&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For asthma and COPD patients, this is a feasibility study to explore the use of gas MRI lung&#xD;
      imaging techniques in tracking disease progression over a 6 year time period. Participants&#xD;
      will have a baseline MRI scanning session and then be asked to come for repeat scans after 3&#xD;
      and 6 years.&#xD;
&#xD;
      Participants will attend for 3 visits, once at baseline, at 3years and 6 years. Each visit is&#xD;
      split over 2 days should occur within one week. This is to ensure eligibility for MRI&#xD;
      scanning.&#xD;
&#xD;
      At the eligibility visit the research team discuss study with patient and obtain informed&#xD;
      consent. An MRI Screening Form is used to identify any contra-indications to MRI scanning.&#xD;
      The participant will be asked further questions about their health, current diagnosis and any&#xD;
      current treatments, smoking history, and about any exposure to pollutants either at home or&#xD;
      at work. Women will be asked to take a urine pregnancy test, to ensure pregnant women are&#xD;
      excluded from the study. The study doctor will perform a brief cardio-respiratory examination&#xD;
      to check that it is safe for the patient to undertake the study. At the MRI scanning visit&#xD;
      the participant will have a series of MRI scans, firstly using Xenon gas, then after a short&#xD;
      break a they will have a second set of scans using 19F perfluoropropane gas. The participant&#xD;
      will also undertake some simple lung function tests.&#xD;
&#xD;
      For COVID patients, this is pilot observational study using nationally unique MR imaging&#xD;
      methods to investigate the acute and long-term pathophysiology of COVID-19 infection and the&#xD;
      resulting changes seen in the lung, pulmonary vasculature and heart of patients with COVID-19&#xD;
      over the course of 12months.&#xD;
&#xD;
      Patients will attend for up to 5 visits. These are at baseline (patient may still be&#xD;
      hospitalised, or this may be shortly after discharge) and 6, 12, 24 and 52 weeks post&#xD;
      discharge. These visit timelines are designed to match with clinical follow up timelines for&#xD;
      hospitalised patients. After the initial approach and consent patients will be screened for&#xD;
      eligibility using the MRI scanning checklist. Patients who are still hospitalised or have&#xD;
      significant ongoing respiratory problems will undertake a test gas inhalation under close&#xD;
      supervision to ensure that this is tolerated prior to MRI scanning. A renal function blood&#xD;
      test will be undertaken if required. For some non-hospitalised patients this will require an&#xD;
      additional visit.&#xD;
&#xD;
      At the first MRI scanning visit consent will be taken or re-affirmed if taken prior to this&#xD;
      visit. Medical history and medication check will be taken and women of child bearing age will&#xD;
      undertake a pregancy test. The participant will have a series of MRI scans, firstly using&#xD;
      Xenon gas, then after a short break a they will have a proton MRI which includes using&#xD;
      gadolinium contrast. The participant will also undertake some simple lung function tests,&#xD;
      including spirometry, gas transfer and endoPAT. Lung function tests will only be completed if&#xD;
      the patient is non-infectious.&#xD;
&#xD;
      The repeat assessments at 6, 12, 24 and 52 weeks will be the same as the first visit,&#xD;
      patients will be contacted prior to their repeat visit to repeat the MRI screening form and&#xD;
      confirm eligibility.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">August 2027</completion_date>
  <primary_completion_date type="Anticipated">August 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>%Ventilated volume</measure>
    <time_frame>3-6 years for asthma/COPD patients, 3-12months for COVID-19 participants</time_frame>
    <description>a measurement derived from MRI images that quantifies the relative amount of lung that is ventilated, corrected for size.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Asthma</condition>
  <condition>COPD</condition>
  <condition>Covid19</condition>
  <condition>Long COVID</condition>
  <arm_group>
    <arm_group_label>Asthma Patients</arm_group_label>
    <description>Adults with physician diagnosis of stable asthma (BTS guideline Step 3 or above).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD Patients</arm_group_label>
    <description>Adults with Stage 3 or 4 COPD (as defined by GOLD guideline 2018)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICU COVID-19</arm_group_label>
    <description>Adults who have been hospitalised on ICU with COVID-19 (requiring CPAP or mechanical ventilation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate/Severe COVID-19</arm_group_label>
    <description>Adults hospitalised with COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild- Non-hospitalised COVID-19</arm_group_label>
    <description>Adult with proven COVID-19 infection, not hospitalised for COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-hospitalised symptomatic (long-COVID group)</arm_group_label>
    <description>Patients presenting at secondary care clinics post COVID-19 with ongoing symptoms.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Asthma/COPD/COVID-19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Asthma patients&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          1. Adults aged 18 years or over.&#xD;
&#xD;
          2. Physician diagnosis of stable asthma (BTS guideline Step 3 or above).&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Recent asthma exacerbation requiring steroids and/or antibiotics in the 6 weeks prior&#xD;
             to a study visit.&#xD;
&#xD;
          2. Asthma deemed by a physician to be unstable or in an active treatment modification&#xD;
             phase.&#xD;
&#xD;
          3. Pregnancy (determined by urine pregnancy test for pre-menopausal women at the&#xD;
             screening (V1) or eligibility visits (V3, V5).&#xD;
&#xD;
          4. Resting blood oxygen saturations (SaO2) &lt; 90% in room air, as measured by oximeter.&#xD;
&#xD;
          5. Inability to comfortably lie supine.&#xD;
&#xD;
          6. Any contraindication(s) to MRI scanning as per the MRI Screening Form and standard&#xD;
             operating procedure used by the Unit of Academic Radiology, Sheffield.&#xD;
&#xD;
          7. Disease or co-morbidity of sufficient severity as to make survival until 6 year follow&#xD;
             up unlikely, as deemed by study clinician.&#xD;
&#xD;
        COPD patients&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          1. Adults aged 18 years or over.&#xD;
&#xD;
          2. Stage 3 or stage 4 COPD as defined by GOLD guidelines 2018,&#xD;
             (https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pd&#xD;
             f) .&#xD;
&#xD;
          3. FEV1:FVC &lt;0.7 (spirometry results).&#xD;
&#xD;
          4. FEV1 &lt; 50% predicted (spirometry results). N.B. spirometry results that have been&#xD;
             performed as part of a patient's normal clinical care within 6 months of study visit 1&#xD;
             may be used for definition of disease status and inclusion into the study;&#xD;
             alternatively if no spirometry result is available it will be performed at visit 1.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Recent COPD exacerbation requiring steroids and/or antibiotics in the 6 weeks prior to&#xD;
             a study visit.&#xD;
&#xD;
          2. COPD deemed by a physician to be unstable or in an active treatment modification&#xD;
             phase, including the active phase of pulmonary rehabilitation.&#xD;
&#xD;
          3. Pregnancy (determined by urine pregnancy test for pre-menopausal women at the&#xD;
             screening (V1) or eligibility visits (V3, V5).&#xD;
&#xD;
          4. Significant heart failure as assessed by clinician.&#xD;
&#xD;
          5. Resting blood oxygen saturations (SaO2) &lt; 90% in room air, as measured by oximeter.&#xD;
&#xD;
          6. Inability to comfortably lie supine.&#xD;
&#xD;
          7. Any contraindication(s) to MRI scanning as per the MRI questionnaire and standard&#xD;
             operating procedure used by the Unit of Academic Radiology, Sheffield.&#xD;
&#xD;
          8. Disease or co-morbidity of sufficient severity as to make survival until 6 year follow&#xD;
             up unlikely, as deemed by study clinician.&#xD;
&#xD;
        ICU COVID-19&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          1. Adult over 18&#xD;
&#xD;
          2. Proven COVID-19&#xD;
&#xD;
          3. Hospitalised/previously hospitalised on ICU requiring CPAP or mechanical ventilation&#xD;
&#xD;
          4. Able to give informed consent&#xD;
&#xD;
          5. For currently hospitalised participants, or those with significant on-going&#xD;
             respiratory problems - Tolerates test inhalation of non-polarised gas according to&#xD;
             supervising clinicians' judgement AND SaO2 do not fall below 80%&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. No previous diagnosed respiratory disease with the exception of mild asthma, defined&#xD;
             as:&#xD;
&#xD;
               1. no oral steroids in past year&#xD;
&#xD;
               2. -no hospital admissions last year&#xD;
&#xD;
               3. max 500mcg per day BDP or 250mcg fluticasone or equivalent ICS&#xD;
&#xD;
          2. Pregnancy (determined by urine pregnancy test for pre-menopausal women)&#xD;
&#xD;
          3. Significant heart failure as assessed by clinician.&#xD;
&#xD;
          4. Resting blood oxygen saturations (SaO2) &lt; 90%, as measured by oximeter at the time of&#xD;
             scanning.&#xD;
&#xD;
          5. Inability to comfortably lie supine.&#xD;
&#xD;
          6. Any contraindication(s) to MRI scanning or Gadolinium contrast agent as per the MRI&#xD;
             questionnaire and standard operating procedure used by the MRI Unit.&#xD;
&#xD;
        6. Stage 4 or 5 chronic kidney disease, defined by creatinine clearance less than 30 mL/min&#xD;
        as estimated by the Cockcroft-Gault equation (due to gadolinium contrast use). 7. Previous&#xD;
        allergy to gadolinium contrast. 8. Significant co-morbidity to make enrolment unsuitable,&#xD;
        as deemed by study clinician.&#xD;
&#xD;
        Moderate/Severe COVID-19&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          1. Adult over 18&#xD;
&#xD;
          2. Proven COVID-19&#xD;
&#xD;
          3. Hospitalised/previously hospitalised with a diagnosis of pneumonia (chest X-ray or CT&#xD;
             scan consistent with COVID-19 infection)&#xD;
&#xD;
          4. Whilst hospitalised had new onset oxygenation impairment defined as:&#xD;
&#xD;
             a. An SpO2 â‰¤93% on room air and/or requiring additional oxygen to maintain&#xD;
             satisfactory oxygenation&#xD;
&#xD;
          5. Able to give informed consent&#xD;
&#xD;
          6. For currently hospitalised participants, or those with significant on-going&#xD;
             respiratory problems - Tolerates test inhalation of non-polarised gas according to&#xD;
             supervising clinicians judgement AND SaO2 do not fall below 80%&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. No previous diagnosed respiratory disease with the exception of mild asthma, defined&#xD;
             as:&#xD;
&#xD;
               1. no oral steroids in past year&#xD;
&#xD;
               2. -no hospital admissions last year&#xD;
&#xD;
               3. max 500mcg per day BDP or 250mcg fluticasone or equivalent ICS&#xD;
&#xD;
          2. Pregnancy (determined by urine pregnancy test for pre-menopausal women)&#xD;
&#xD;
          3. Significant heart failure as assessed by clinician.&#xD;
&#xD;
          4. Resting blood oxygen saturations (SaO2) &lt; 90%, as measured by oximeter at time of MRI&#xD;
             scanning.&#xD;
&#xD;
          5. Inability to comfortably lie supine.&#xD;
&#xD;
          6. Any contraindication(s) to MRI scanning or Gadolinium contrast agent as per the MRI&#xD;
             questionnaire and standard operating procedure used by the MRI Unit.&#xD;
&#xD;
          7. Stage 4 or 5 chronic kidney disease, defined by creatinine clearance less than 30&#xD;
             mL/min as estimated by the Cockcroft-Gault equation (due to gadolinium contrast use).&#xD;
&#xD;
          8. Previous allergy to gadolinium contrast.&#xD;
&#xD;
          9. Significant co-morbidity to make enrolment unsuitable, as deemed by study clinician.&#xD;
&#xD;
        Mild- Non-hospitalised&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          1. Adult over 18&#xD;
&#xD;
          2. Proven COVID-19&#xD;
&#xD;
          3. Not hospitalised for COVID-19&#xD;
&#xD;
          4. Able to give informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. No previous diagnosed respiratory disease with the exception of mild asthma, defined&#xD;
             as:&#xD;
&#xD;
               1. no oral steroids in past year&#xD;
&#xD;
               2. -no hospital admissions last year&#xD;
&#xD;
               3. max 500mcg per day BDP or 250mcg fluticasone or equivalent ICS&#xD;
&#xD;
          2. Pregnancy (determined by urine pregnancy test for pre-menopausal women)&#xD;
&#xD;
          3. Significant heart failure as assessed by clinician.&#xD;
&#xD;
          4. Resting blood oxygen saturations (SaO2) &lt; 90%, as measured by oximeter.&#xD;
&#xD;
          5. Inability to comfortably lie supine.&#xD;
&#xD;
          6. Any contraindication(s) to MRI scanning or Gadolinium contrast agent as per the MRI&#xD;
             questionnaire and standard operating procedure used by the MRI Unit.&#xD;
&#xD;
          7. Stage 4 or 5 chronic kidney disease, defined by creatinine clearance less than 30&#xD;
             mL/min as estimated by the Cockcroft-Gault equation (due to gadolinium contrast use).&#xD;
&#xD;
          8. Previous allergy to gadolinium contrast.&#xD;
&#xD;
          9. Significant co-morbidity to make enrolment unsuitable, as deemed by study clinician.&#xD;
&#xD;
        Non-hospitalised symptomatic (long-COVID group)&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          1. Adult over 18&#xD;
&#xD;
          2. Proven COVID-19&#xD;
&#xD;
          3. Not hospitalised for COVID-19&#xD;
&#xD;
          4. Able to give informed consent&#xD;
&#xD;
          5. Attended secondary care clinic with on-going symptoms.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. No previous diagnosed respiratory disease with the exception of mild asthma, defined&#xD;
             as:&#xD;
&#xD;
               1. no oral steroids in past year&#xD;
&#xD;
               2. no hospital admissions last year&#xD;
&#xD;
               3. max 500mcg per day BDP or 250mcg fluticasone or equivalent ICS&#xD;
&#xD;
          2. Pregnancy (determined by urine pregnancy test for pre-menopausal women)&#xD;
&#xD;
          3. Significant heart failure as assessed by clinician.&#xD;
&#xD;
          4. Resting blood oxygen saturations (SaO2) &lt; 90%, as measured by oximeter at the time of&#xD;
             scanning.&#xD;
&#xD;
          5. Inability to comfortably lie supine.&#xD;
&#xD;
          6. Any contraindication(s) to MRI scanning or Gadolinium contrast agent as per the MRI&#xD;
             questionnaire and standard operating procedure used by the MRI Unit.&#xD;
&#xD;
          7. Stage 4 or 5 chronic kidney disease, defined by creatinine clearance less than 30&#xD;
             mL/min as estimated by the Cockcroft-Gault equation (due to gadolinium contrast use).&#xD;
&#xD;
          8. Previous allergy to gadolinium contrast.&#xD;
&#xD;
          9. Significant co-morbidity to make enrollment unsuitable, as deemed by study clinician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jim M Wild</last_name>
    <phone>+44 114 215 9141</phone>
    <email>polaris@sheffield.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Unit of Radiology, Univeristy of Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Wild, Professor</last_name>
      <phone>+44 114 215 9141</phone>
      <email>polaris@sheffield.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rod Lawson, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian Sabroe, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger Thompson, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Collini, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gary Mills, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

